
Congress has passed a law designed to get advanced diagnostic tests to patients more quickly and to promote personalized care for patients.
Congress has passed a law designed to get advanced diagnostic tests to patients more quickly and to promote personalized care for patients.
As the administration looks at improving the insurance marketplace, patient advocates are developing a wish list of modifications to ensure that it is more patient focused.
People with chronic conditions need effective and affordable drugs to live longer and better lives. Unfortunately, regulations covering plans in state exchanges may impede access.
People with chronic conditions need effective and affordable drugs to live longer and better lives. Unfortunately, regulations covering plans in state exchanges may impede access.
A tool for organizing patient concerns and comments to ensure that the FDA captures the comprehensive information it needs to integrate patient perspectives throughout the agency's review process.
Usability criteria will help investigators structure CER to answer the questions that are most important to patients, their family caregivers, healthcare providers, and policy makers.
Use of a simple model developed by the patient advocacy community could facilitate valuable dialogue between the FDA and people with chronic conditions.
In the interest of advancing research for new treatments and cures, problems in the HIPAA privacy rule must be addressed by all health community stakeholders.
As the Supreme Court nears its decision on the constitutionality of ACA, healthcare reform is already pushing inexorably forward.
Two initiatives currently under way will support the generation of new insight into the safety of medicines and treatment effectiveness.
WHO'S commitment to addressing the impact of 4 common noncommunicable diseases will ultimately lead to improvements for patients with a broad range of chronic conditions.
A bill introduced in the US House of Representatives, the MODDERN Cures Solution, would ensure that science, not patent law, drives development of new therapies.
This is the second of a 2-part series on the development of the essential health benefit package prescribed under the Patient Protection and Affordable Care Act.
Published: June 15th 2011 | Updated:
Published: August 8th 2011 | Updated:
Published: December 9th 2011 | Updated:
Published: April 5th 2012 | Updated:
Published: May 31st 2012 | Updated:
Published: August 2nd 2012 | Updated: